A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

Required: ESR1 expression (positive)

presence of ER and/or PR expression

Required: PR (PGR) expression (positive)

presence of ER and/or PR expression

Required: HER2 (ERBB2) wild-type (absence of HER2 expression)

HER2-negative (characterized by the absence of HER2 expression)

Must have received: endocrine therapy — locally advanced or metastatic breast cancer

disease progression during or following endocrine therapy

Must have received: standard of care therapy — locally advanced or metastatic ovarian cancer or endometrial cancer

progressed during or following prior standard of care therapy

Cannot have received: antitumor drug or investigational drug

Exception: washout periods specified for each class

received an antitumor drug or investigational drug at the following time intervals: Chemotherapy, targeted small molecule therapy or radiotherapy (except palliative radiotherapy and the radiotherapy area do not include the proposed target lesion) ≤ 14 days. The wash-out period for TKI drugs is more than 5 half-lives could enroll for their shorter half-life. Immunotherapy or cell therapy (i.e. chimeric antigen receptor T cell therapy) ≤ 28 days; Other cell therapy must be discussed with the investigators to determine eligibility. Monoclonal antibodies ≤ 28 days for anticancer therapy. Anti-tumor Chinese medicine which approved by the agency ≤ 14 days. Immunosuppressive therapy for any reason ≤ 7 days. Fulvestrant ≤ 250 days (5 half-lives). All other investigational drugs or devices ≤ 28 days or 5 half-lives before the first dosing administration (whichever is shorter).